ALT5 Sigma Corporation Reports Revenue Growth to $6.4 Million in Latest 10-Q Filing

ALT5 Sigma Corporation reported significant financial developments in its latest 10-Q filing for the period ending June 28, 2025. The company generated revenues of $6.4 million for the thirteen weeks ended June 28, 2025, a substantial increase from $2.2 million in the same period last year. For the twenty-six weeks, revenues reached $11.9 million, compared to $2.2 million in the prior year. The gross profit for the quarter was $2.8 million, reflecting a gross margin of 43.5%, although this was a decrease from 50.6% in the previous year. The operating loss for the quarter was $2.1 million, slightly improved from a loss of $2.4 million in the same quarter last year.

The financial performance was bolstered by the acquisitions of ALT5 Subsidiary in May 2024 and Mswipe in May 2025, which contributed to the revenue growth. The company’s selling, general, and administrative expenses increased to $4.9 million for the quarter, up from $3.5 million a year earlier, primarily due to costs associated with these acquisitions. The net loss for the quarter was $9.1 million, compared to a net income of $0.6 million in the same period last year, largely driven by increased operational costs and interest expenses.

Operationally, ALT5 Sigma has seen a notable increase in its customer base and engagement metrics, particularly in its Fintech segment, which now includes the newly acquired Mswipe. The company reported a significant rise in digital asset transactions, although specific user statistics were not disclosed. The company’s total assets increased to $94.7 million as of June 28, 2025, up from $82.4 million at the end of the previous fiscal year, driven by the acquisitions and an increase in cash reserves to $9.6 million.

Looking ahead, ALT5 Sigma is focused on expanding its market presence and enhancing its product offerings. The company plans to utilize proceeds from a registered direct offering to settle existing litigation, pay down debt, and fund ongoing operations. Additionally, the company is contemplating further acquisitions and investments in its biotechnology segment, which has been classified as discontinued operations following the planned separation of its healthcare assets. The management remains optimistic about future growth, although it acknowledges the need for additional capital to support its strategic initiatives.